Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a randomized prospective multicenter clinical trial

被引：0
|
作者：
Waltregny, D
Boca, P
Nicolas, H
Youssef, E
Jeukenne, M
Bouffioux, C
Coppens, L
Andrianne, R
Bonnet, P
De Leval, J
机构：
来源：
JOURNAL OF UROLOGY | 2002年 / 167卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [21] INTERMITTENT CHEMOTHERAPY FOR METASTATIC HORMONE REFRACTORY PROSTATE CANCER: LONG TERM RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL
    Ozen, Haluk
    Akdogan, Bulent
    Ergen, Ali
    Gunay, Levent Mert
    Kirdal, Yeter
    Inci, Kubilay
    Bilen, Cenk Yucel
    JOURNAL OF UROLOGY, 2011, 185 (04): : E285 - E285
  • [22] Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients
    Leibowitz, RL
    Tucker, SJ
    ONCOLOGIST, 2001, 6 (02): : 177 - 182
  • [23] A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial
    Lin, J.
    Beer, T. M.
    Ryan, C. J.
    Mathew, P.
    Wilding, G.
    Morris, M.
    Callahan, J. A.
    Gordon, G.
    Reich, S.
    Carducci, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naive prostate cancer patients with bone metastases: Results of ZAPCA study.
    Kamba, Tomomi
    Kamoto, Toshiyuki
    Shimizu, Yousuke
    Namiki, Shunichi
    Fujimoto, Kiyohide
    Kawanishi, Hiroaki
    Sato, Fuminori
    Narita, Shintaro
    Satoh, Takefumi
    Saito, Hideo
    Sugimoto, Mikio
    Teishima, Jun
    Masumori, Naoya
    Egawa, Shin
    Sakai, Hideki
    Okada, Yusaku
    Terachi, Toshiro
    Ogawa, Osamu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [25] Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer
    Kuriyama, M
    Takahashi, Y
    Sahashi, M
    Ono, Y
    Tanaka, T
    Shimizu, H
    Ohshima, S
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (01) : 18 - 24
  • [26] A COMPARISON OF ZOLADEX AND DES IN THE TREATMENT OF ADVANCED PROSTATE-CANCER - RESULTS OF A RANDOMIZED, MULTICENTER TRIAL
    CITRIN, DL
    RESNICK, MI
    GUINAN, P
    ALBUSSAM, N
    SCOTT, M
    GAU, TC
    KENNEALEY, GT
    PROSTATE, 1991, 18 (02): : 139 - 146
  • [27] THE RATIONALE AND FIRST CLINICAL-RESULTS WITH INTERMITTENT ANDROGEN SUPPRESSION IN PATIENTS WITH ADVANCED PROSTATE-CANCER
    BRUCHOVSKY, N
    GOLDENBERG, SL
    RENNIE, PS
    GLEAVE, M
    UROLOGE-AUSGABE A, 1995, 34 (05): : 389 - 392
  • [28] INTERMITTENT VERSUS CONTINUOUS ANDROGEN DEPRIVATION IN PATIENTS WITH RELAPSING OR LOCALLY ADVANCED PROSTATE CANCER: A PHASE 3B RANDOMIZED STUDY (ICELAND)
    Schulman, Claude
    Cornel, Erik
    Matveev, Vsevolod
    Schraml, Jan
    Bensadoun, Henri
    Warnack, Wolfgang
    Persad, Raj
    Salagierski, Marek
    Gomez Viega, Francisco
    Baskin-Bey, Edwina
    Lopez, Beatriz
    Tombal, Bertrand
    JOURNAL OF UROLOGY, 2015, 193 (04): : E938 - E938
  • [29] A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial
    Tomomi Kamba
    Toshiyuki Kamoto
    Shinichiro Maruo
    Takashi Kikuchi
    Yosuke Shimizu
    Shunichi Namiki
    Kiyohide Fujimoto
    Hiroaki Kawanishi
    Fuminori Sato
    Shintaro Narita
    Takefumi Satoh
    Hideo Saito
    Mikio Sugimoto
    Jun Teishima
    Naoya Masumori
    Shin Egawa
    Hideki Sakai
    Yusaku Okada
    Toshiro Terachi
    Osamu Ogawa
    International Journal of Clinical Oncology, 2017, 22 : 166 - 173
  • [30] A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial
    Kamba, Tomomi
    Kamoto, Toshiyuki
    Maruo, Shinichiro
    Kikuchi, Takashi
    Shimizu, Yosuke
    Namiki, Shunichi
    Fujimoto, Kiyohide
    Kawanishi, Hiroaki
    Sato, Fuminori
    Narita, Shintaro
    Satoh, Takefumi
    Saito, Hideo
    Sugimoto, Mikio
    Teishima, Jun
    Masumori, Naoya
    Egawa, Shin
    Sakai, Hideki
    Okada, Yusaku
    Terachi, Toshiro
    Ogawa, Osamu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (01) : 166 - 173
12345